After completing the first 14 days of the blinded treatment period, subjects will be given the option to continue on their current randomized therapy, including their current study medication, for an additional 1-2 weeks. On Day 15, a blood sample will be collected to determine the amount of HIV virus in the blood. Once the results from that blood sample are available, subjects will be told the amount of how much HIV virus changed in the blood during the first 14 days of treatment. Subjects will also be told if they were receiving RCV (Racivir®) alone, 3TC (lamivudine, Epivir®) alone, or a combination of RCV (Racivir®) and 3TC (lamivudine, Epivir®).